1.1.1.23: histidinol dehydrogenase
This is an abbreviated version!
For detailed information about histidinol dehydrogenase, go to the full flat file.
Reaction
Synonyms
11412251, BN980_GECA03s06082g, BsHDH, GcHDH, HDH, HIS4 protein, HisD, histidinol dehydrogenase, HLDase, L-histidinol dehydrogenase
ECTree
Advanced search results
Inhibitors
Inhibitors on EC 1.1.1.23 - histidinol dehydrogenase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
(2S)-2-amino-3-(1H-imidazol-4-yl)-N'-(naphthalen-2-ylsulfonyl)propanehydrazide
-
-
(2S)-2-amino-3-(1H-imidazol-4-yl)-N'-[(4-methylphenyl)sulfonyl]propanehydrazide
-
-
(2S)-2-amino-N'-[(4-bromophenyl)sulfonyl]-3-(1H-imidazol-4-yl)propanehydrazide
-
-
(3S)-3-amino-1-(2,3,4,5,6-pentafluorophenyloxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-(2,3,4,5,6-pentafluorophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-(4-bromophenoxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-(4-bromophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-(4-fluorophenoxy)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-(4-fluorophenylthio)-4-(1H-imidazol-4-yl)butan-2-one dihydrochloride
-
-
(3S)-3-amino-1-[4-(biphenyl-4-ylethynyl)phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
-
(3S)-3-amino-1-[4-(biphenyl-4-ylmethoxy)phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
-
(3S)-3-amino-1-[4-[(4-bromobenzyl)oxy]phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
-
(3S)-3-amino-1-[4-[(4-butylbenzyl)oxy]phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
50% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-1-[4-[(4-tert-butylphenyl)ethynyl]phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
30% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-1-[4-[(E)-2-(biphenyl-4-yl)ethenyl]phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]phenyl)butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[[4-(naphthalen-2-yl)benzyl]oxy]phenyl)butan-2-one
-
complete inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(4-[[4-(trifluoromethyl)benzyl]oxy]phenyl)butan-2-one
-
70% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-yloxy)butan-2-one dihydrochloride
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-(naphthalen-2-ylthio)butan-2-one dihydrochloride
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-(7-phenylhept-1-yn-1-yl)phenyl]butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-(phenylethynyl)phenyl]butan-2-one
-
complete inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(1E)-3-phenylprop-1-en-1-yl]phenyl]butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methoxybenzyl)oxy]phenyl]butan-2-one
-
30% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methylbenzyl)oxy]phenyl]butan-2-one
-
30% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-methylphenyl)ethynyl]phenyl]butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-pentylphenyl)ethynyl]phenyl]butan-2-one
-
30% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(4-phenoxybenzyl)oxy]phenyl]butan-2-one
-
70% inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(E)-2-(4-methylphenyl)ethenyl]phenyl]butan-2-one
-
complete inhibition of pathogen growth in minimal medium at 0.5 mM
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[(E)-2-phenylethenyl]phenyl]butan-2-one
-
-
(3S)-3-amino-4-(1H-imidazol-4-yl)butan-2-one
-
(7R)-1,3-diiodo-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid
-
weaker inhibitor
(7S)-7-[(2,4-difluorophenyl)acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(7S)-7-[(4-bromophenyl)acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(7S)-7-[(4-chlorophenyl)acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(7S)-7-[(4-methylphenyl)acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(7S)-7-[([1,1'-biphenyl]-4-yl)acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(7S)-7-[[4-(7-phenylhept-1-yn-1-yl)phenyl]acetyl]-7,8-dihydroimidazo[1,5-c]pyrimidin-5(6H)-one
-
-
(8S)-8-[2-(biphenyl-4-yl)ethanethioyl]-7,8-dihydroimidazo[1,5-c]pyrimidine-5(6H)-thione
-
1,3-diiodo-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid
-
2-(2,4-difluorophenyl)-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
2-(4-bromophenyl)-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
2-(4-chlorophenyl)-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
2-(4-methylphenyl)-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
2-([1,1'-biphenyl]-4-yl)-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-(4-methoxyphenyl)methylidene]propanehydrazide
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-(4-methylphenyl)methylidene]propanehydrazide
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-(4-nitrophenyl)methylidene]propanehydrazide
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-(4-phenoxyphenyl)methylidene]propanehydrazide
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-(naphthalen-2-yl)methylidene]propanehydrazide
-
2-amino-3-(1H-imidazol-4-yl)-N'-[(E)-phenylmethylidene]propanehydrazide (non-preferred name)
-
2-amino-N'-[(E)-(2-hydroxyphenyl)methylidene]-3-(1H-imidazol-4-yl)propanehydrazide
-
2-amino-N'-[(E)-(4-bromophenyl)methylidene]-3-(1H-imidazol-4-yl)propanehydrazide
-
2-amino-N'-[(E)-(4-chlorophenyl)methylidene]-3-(1H-imidazol-4-yl)propanehydrazide
-
2-amino-N'-[(E)-(4-fluorophenyl)methylidene]-3-(1H-imidazol-4-yl)propanehydrazide
-
2-amino-N'-[(E)-[4-(dimethylamino)phenyl]methylidene]-3-(1H-imidazol-4-yl)propanehydrazide
-
2-[4-(7-phenylhept-1-yn-1-yl)phenyl]-1-[(7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidin-7-yl]ethan-1-one
-
-
5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylic acid
i.e. RJ-278
7-chloro-4-nitro-2,1,3-benzoxadiazole
-
0.1 mM, pseudo first order inactivation, binds to Cys-116 in active site
methyl (7R)-1-chloro-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylate
-
weaker inhibitor
methyl (7S)-5-sulfanylidene-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylate
-
-
methyl 1-chloro-5-oxo-5,6,7,8-tetrahydroimidazo[1,5-c]pyrimidine-7-carboxylate
-
pyridoxal 5'-phosphate
-
100 mM, 62.5% inhibition, concentration dependent, almost completely reversible
-
-
(2S)-2-amino-N'-(biphenyl-4-ylsulfonyl)-3-(1H-imidazol-4-yl)propanehydrazide
-
-
causes strong in vivo inhibition and growth inhibition
(3S)-3-amino-1-[4-(benzyloxy)phenyl]-4-(1H-imidazol-4-yl)butan-2-one
a nanomolar inhibitor, binding structure, overview
(3S)-3-amino-1-[4-(benzyloxy)phenyl]-4-(1H-imidazol-4-yl)butan-2-one
-
-
causes strong in vivo inhibition and growth inhibition
(3S)-3-amino-4-(1H-imidazol-4-yl)-1-[4-[4-(phenylethynyl)benzyl]phenyl]butan-2-one
-
-
growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
-
growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
-
growth of cells is inhibited in minimal medium, multiplication of cells in human macrophages is totally abolished. No biological effect in rich medium
118% activity at 0.1 mM, 135% at 1 mM, slightly inhibitory above 10 mM
HgCl2
-
0.1 mM, 80% inhibition, pH 9.4
-
75% inhibition with one equivalent per subunit
N-(4-dimethylamino-3,5-dinitrophenyl)-maleimide
-
-
p-chloromercuribenzoate
-
75% inhibition with two equivalents per subunit
p-chloromercuribenzoate
-
2.5 mM, 60% inhibition
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-
additional information
-
synthesis and evaluation of alpha-O-arylketones and alpha-S-arylketones derived from histidine
-
additional information
-
exploration of enzyme inhibitors for potential application as antimicrobial drugs
-
additional information
-
design, synthesis and evaluation of 19 potential HDH inhibitors, molecular modeling and docking study, overview
-
additional information
-
synthesis of a family of oxo- and thioxo-imidazo[1,5-c]pyrimidines, potential enzyme inhibitors. These oxo- and thioxo-derivatives can improve dramatically the efficiency of the histidine protection pathway for the synthesis of histidine analogues, overview
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-
additional information
-
5% dimethyl sulfoxide or methyl N-[(trifluoromethoxy)carbonyl]-L-histidinate trifluoroacetate fails to exert any growth inhibitory activity
-
additional information
screening of substrate analog inhibitors of histidinol dehydrogenase, and docking analysis of these antifungal agents, overview
-
additional information
-
screening of substrate analog inhibitors of histidinol dehydrogenase, and docking analysis of these antifungal agents, overview
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-
additional information
synthesis of hydrazones derived from L-histidine as enzyme inhibitors in the low micromolar range, overview. Molecular docking study and enzyme-inhibitor complex structure analysis
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs. Enzyme inactivation by chelating agents
-
additional information
exploration of enzyme inhibitors for potential application as novel antimicrobial drugs
-